Cui Zhao, Zhao Juan, Jia Xiao-Yu, Zhu Sai-Nan, Jin Qi-Zhuang, Cheng Xu-Yang, Zhao Ming-Hui
From Renal Division (ZC, JZ, XYJ, QZJ, XYC, MHZ), Department of Medicine, and Department of Biostatistics (SNZ), Peking University First Hospital, Beijing; Institute of Nephrology (ZC, JZ, XYJ, QZJ, XYC, MHZ), Peking University, Beijing; and Key Laboratory of Renal Disease (ZC, JZ, XYJ, QZJ, XYC, MHZ), Ministry of Health of China, Beijing.
Medicine (Baltimore). 2011 Sep;90(5):303-311. doi: 10.1097/MD.0b013e31822f6f68.
Anti-glomerular basement membrane (GBM) disease usually presents with rapidly progressive glomerulonephritis accompanied by pulmonary hemorrhage. The low incidence and fulminant course of disease preclude a large randomized controlled study to define the benefits of any given therapy. We conducted a retrospective survey of 221 consecutive patients seen from 1998 to 2008 in our hospital, and report here the patient and renal survival and the risk factors affecting the outcomes. Considering the similar clinical features of the patients, we could compare the effects of 3 different treatment regimens: 1) combination therapy of plasmapheresis and immunosuppression, 2) steroids and cytotoxic agents, and 3) steroids alone.The patient and renal survival rates were 72.7% and 25.0%, respectively, at 1 year after disease presentation. The serum level of anti-GBM antibodies (increased by 20 U/mL; hazard ratio [HR], 1.16; p = 0.009) and the presentation of positive antineutrophil cytoplasmic antibodies (ANCA) (HR, 2.18; p = 0.028) were independent predictors for patient death. The serum creatinine at presentation (doubling from 1.5 mg/dL; HR, 2.07; p < 0.001) was an independent predictor for renal failure.The combination therapy of plasmapheresis plus corticosteroids and cyclophosphamide had an overall beneficial effect on both patient survival (HR for patient mortality, 0.31; p = 0.001) and renal survival (HR for renal failure, 0.60; p = 0.032), particularly patient survival for those with Goodpasture syndrome (HR for patient mortality, 0.29; p = 0.004) and renal survival for those with anti-GBM nephritis with initial serum creatinine over 6.8 mg/dL (HR for renal failure, 0.52; p = 0.014). The treatment with corticosteroids plus cyclophosphamide was found not to improve the renal outcome of disease (p = 0.73). In conclusion, the combination therapy was preferred for patients with anti-GBM disease, especially those with pulmonary hemorrhage or severe renal damage. Early diagnosis was crucial to improving outcomes.
抗肾小球基底膜(GBM)病通常表现为快速进展性肾小球肾炎并伴有肺出血。该病发病率低且病程凶险,妨碍了通过大规模随机对照研究来确定任何特定治疗方法的益处。我们对1998年至2008年在我院连续就诊的221例患者进行了回顾性调查,并在此报告患者生存率、肾脏生存率以及影响预后的危险因素。考虑到患者具有相似的临床特征,我们比较了3种不同治疗方案的效果:1)血浆置换与免疫抑制联合治疗;2)类固醇与细胞毒性药物治疗;3)单纯类固醇治疗。疾病出现后1年时,患者生存率和肾脏生存率分别为72.7%和25.0%。抗GBM抗体血清水平(升高20 U/mL;风险比[HR],1.16;p = 0.009)以及抗中性粒细胞胞浆抗体(ANCA)阳性表现(HR,2.18;p = 0.028)是患者死亡的独立预测因素。疾病出现时的血清肌酐水平(从1.5 mg/dL翻倍;HR,2.07;p < 0.001)是肾衰竭的独立预测因素。血浆置换联合皮质类固醇和环磷酰胺的治疗方案对患者生存率(患者死亡率的HR,0.31;p = 0.001)和肾脏生存率(肾衰竭的HR,0.60;p = 0.032)均具有总体有益作用,对于患有Goodpasture综合征患者的生存率(患者死亡率的HR,0.29;p = 0.004)以及初始血清肌酐超过6.8 mg/dL的抗GBM肾炎患者的肾脏生存率(肾衰竭的HR,0.52;p = 0.014)尤其如此。发现皮质类固醇联合环磷酰胺治疗并不能改善疾病的肾脏预后(p = 0.73)。总之,抗GBM病患者首选联合治疗方案,尤其是那些伴有肺出血或严重肾损伤的患者。早期诊断对于改善预后至关重要。